harmaline has been researched along with Disease Models, Animal in 34 studies
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.
harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a pig model, tremor was induced with harmaline and measured with wireless accelerometers attached to the limbs." | 7.88 | Development of Harmaline-induced Tremor in a Swine Model. ( Chang, SY; Cheng, L; Jang, DP; Kang, SI; Kim, I; Knight, E; Lee, J, 2018) |
| "Harmaline was injected at a dose of 15 mg/kg ip and tremor was measured automatically in force-plate actimeters by an increased averaged power in the frequency band of 9-15 Hz (AP2) and by tremor index (a difference in power between AP2 and averaged power in the frequency band of 0-8 Hz)." | 7.85 | Tremorolytic effect of 5'-chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats. ( Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2017) |
| "To study the effect of pretreatment with low doses of vanillin, a flavoring agent used as a food additive, on harmaline-induced tremor in rats." | 7.85 | Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats. ( Abdulrahman, AA; Arshaduddin, M; Faisal, K; Meshref, AA, 2017) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 7.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "In this study, we examined the effect of bilateral intra-basolateral amygdala (intra-BLA) microinjections of dopamine receptor agents on amnesia induced by a β-carboline alkaloid, harmaline in mice." | 7.83 | Harmaline-induced amnesia: Possible role of the amygdala dopaminergic system. ( Khakpai, F; Meskarian, M; Nasehi, M; Zarrindast, MR, 2016) |
| "Recent work exploring the use of high-molecular weight alcohols to treat essential tremor (ET) has identified octanoic acid as a potential novel tremor-suppressing agent." | 7.78 | Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. ( Brown, T; Dong, C; Hallett, M; Handforth, A; Haubenberger, D; Nahab, FB; Quesada, A; Shin, C, 2012) |
| " We compared the two compounds for behavioral toxicity, effects on cytochrome P450 activity, and efficacy against tremor in the γ-aminobutyric acid type A (GABAA) receptor subunit α1-null mouse, and the harmaline tremor model of essential tremor in wild-type mice." | 7.77 | Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. ( Bui, PH; Handforth, A; Hankinson, O; Homanics, GE; Quesada, A, 2011) |
| " This hypothesis was tested by searching for the expression of the Cx57 transcripts in the mouse cerebellum of the harmaline-tremor model." | 7.76 | Expression of connexin57 in mouse development and in harmaline-tremor model. ( Cicirata, F; Cicirata, V; La Delia, F; Parenti, R; Zappalà, A, 2010) |
| "32 mg/kg sc strongly enhances tremor of forelimbs, head and trunk, hypolocomotion, and ataxia induced by harmaline (7." | 7.75 | Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. ( Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2009) |
| "We studied whether vagus nerve stimulation could suppress tremor in the harmaline tremor model in the rat." | 7.71 | Suppression of harmaline-induced tremor in rats by vagus nerve stimulation. ( Handforth, A; Krahl, SE, 2001) |
| "Recent studies suggest an association between caffeine consumption and tremor." | 7.71 | Effect of acute caffeine on severity of harmaline induced tremor in rats. ( Al-Deeb, S; Al-Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2002) |
| "Pretreatment with agmatine reduced the percent tremor duration and intensity of tremor induced by harmaline, without affecting the tremor frequency." | 5.62 | Agmatine has beneficial effect on harmaline-induced essential tremor in rat. ( Akman, Ö; Arıcıoğlu, F; Ateş, N; Güllü, K; Karson, A; Utkan, T, 2021) |
| "In a pig model, tremor was induced with harmaline and measured with wireless accelerometers attached to the limbs." | 3.88 | Development of Harmaline-induced Tremor in a Swine Model. ( Chang, SY; Cheng, L; Jang, DP; Kang, SI; Kim, I; Knight, E; Lee, J, 2018) |
| "Harmaline was injected at a dose of 15 mg/kg ip and tremor was measured automatically in force-plate actimeters by an increased averaged power in the frequency band of 9-15 Hz (AP2) and by tremor index (a difference in power between AP2 and averaged power in the frequency band of 0-8 Hz)." | 3.85 | Tremorolytic effect of 5'-chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats. ( Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2017) |
| "To study the effect of pretreatment with low doses of vanillin, a flavoring agent used as a food additive, on harmaline-induced tremor in rats." | 3.85 | Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats. ( Abdulrahman, AA; Arshaduddin, M; Faisal, K; Meshref, AA, 2017) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 3.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "In this study, we examined the effect of bilateral intra-basolateral amygdala (intra-BLA) microinjections of dopamine receptor agents on amnesia induced by a β-carboline alkaloid, harmaline in mice." | 3.83 | Harmaline-induced amnesia: Possible role of the amygdala dopaminergic system. ( Khakpai, F; Meskarian, M; Nasehi, M; Zarrindast, MR, 2016) |
| "Hybrid tremor analysis of harmaline-induced and genetic tremor in mice revealed that two authentic tremor frequencies for each type of tremor were conserved and showed an opposite dependence on CaV3." | 3.81 | Heterogeneity of tremor mechanisms assessed by tremor-related cortical potential in mice. ( Chang, KY; Choi, JH; Kim, D; Kim, S; Kim, Y; Lee, C; Paek, SH; Park, YG, 2015) |
| "Recent work exploring the use of high-molecular weight alcohols to treat essential tremor (ET) has identified octanoic acid as a potential novel tremor-suppressing agent." | 3.78 | Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. ( Brown, T; Dong, C; Hallett, M; Handforth, A; Haubenberger, D; Nahab, FB; Quesada, A; Shin, C, 2012) |
| " We compared the two compounds for behavioral toxicity, effects on cytochrome P450 activity, and efficacy against tremor in the γ-aminobutyric acid type A (GABAA) receptor subunit α1-null mouse, and the harmaline tremor model of essential tremor in wild-type mice." | 3.77 | Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. ( Bui, PH; Handforth, A; Hankinson, O; Homanics, GE; Quesada, A, 2011) |
| " This hypothesis was tested by searching for the expression of the Cx57 transcripts in the mouse cerebellum of the harmaline-tremor model." | 3.76 | Expression of connexin57 in mouse development and in harmaline-tremor model. ( Cicirata, F; Cicirata, V; La Delia, F; Parenti, R; Zappalà, A, 2010) |
| "32 mg/kg sc strongly enhances tremor of forelimbs, head and trunk, hypolocomotion, and ataxia induced by harmaline (7." | 3.75 | Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. ( Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2009) |
| "3 to 30 mg/kg), a new anticonvulsant drug, in a model of essential tremor in comparison to the reference compounds propranolol and primidone." | 3.74 | Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. ( Freitag, J; Lekieffre, D; Stöhr, T, 2008) |
| " As a positive control for postural instability, wild type mice were injected with harmaline, a tremorigenic agent, and the average areas of the 95% confidence ellipse, which measures 95% of the CoP trajectory values recorded in a single trial, were measured." | 3.74 | Quantitative measurement of postural sway in mouse models of human neurodegenerative disease. ( Colton, CA; Dawson, HN; Dodd, M; Ho, V; Hutchinson, D; Schmitt, D; Zumwalt, AC, 2007) |
| "We studied whether vagus nerve stimulation could suppress tremor in the harmaline tremor model in the rat." | 3.71 | Suppression of harmaline-induced tremor in rats by vagus nerve stimulation. ( Handforth, A; Krahl, SE, 2001) |
| "Recent studies suggest an association between caffeine consumption and tremor." | 3.71 | Effect of acute caffeine on severity of harmaline induced tremor in rats. ( Al-Deeb, S; Al-Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2002) |
| "Animal models of tremor have been widely used in experimental neurology, because they are an indispensable requirement for understanding the pathophysiology of human tremor disorders and the development of new therapeutic agents." | 2.40 | Animal models of tremor. ( Deuschl, G; Sievers, J; Wilms, H, 1999) |
| "Pretreatment with agmatine reduced the percent tremor duration and intensity of tremor induced by harmaline, without affecting the tremor frequency." | 1.62 | Agmatine has beneficial effect on harmaline-induced essential tremor in rat. ( Akman, Ö; Arıcıoğlu, F; Ateş, N; Güllü, K; Karson, A; Utkan, T, 2021) |
| "Essential tremor is a common disorder that lacks molecular targets for therapeutic development." | 1.36 | T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. ( Covey, DF; Handforth, A; Homanics, GE; Krishnan, K; Lee, JY; Martin, FC; Quesada, A; Sakimura, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.88) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 10 (29.41) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Alijanpour, S | 1 |
| Jafaripour, S | 1 |
| Ghasemzadeh, Z | 1 |
| Khakpai, F | 2 |
| Zarrindast, MR | 3 |
| Akman, Ö | 1 |
| Utkan, T | 1 |
| Arıcıoğlu, F | 1 |
| Güllü, K | 1 |
| Ateş, N | 1 |
| Karson, A | 1 |
| Kosmowska, B | 2 |
| Ossowska, K | 3 |
| Głowacka, U | 2 |
| Wardas, J | 3 |
| Dahmardeh, N | 1 |
| Asadi-Shekaari, M | 1 |
| Arjmand, S | 1 |
| Kalantaripour, T | 1 |
| Basiri, M | 1 |
| Shabani, M | 2 |
| Lee, J | 2 |
| Kim, I | 1 |
| Knight, E | 1 |
| Cheng, L | 1 |
| Kang, SI | 1 |
| Jang, DP | 1 |
| Chang, SY | 1 |
| Egorova, PA | 1 |
| Gavrilova, AV | 1 |
| Bezprozvanny, IB | 1 |
| Ebrahimi-Ghiri, M | 1 |
| Nasehi, M | 2 |
| Carlsen, EMM | 1 |
| Amrutkar, DV | 1 |
| Sandager-Nielsen, K | 1 |
| Perrier, JF | 1 |
| Vilela-Filho, O | 1 |
| Ferraz, FP | 1 |
| Barros, BA | 1 |
| Silva, LO | 1 |
| Anunciação, SF | 1 |
| Souza, JT | 1 |
| Silva, DJ | 1 |
| Leite, MB | 1 |
| Atayde, IB | 1 |
| Ragazzo, PC | 1 |
| Barreto, PG | 1 |
| Nobrega, MA | 1 |
| Araujo, MR | 1 |
| Santos, MR | 1 |
| Ala, VH | 1 |
| Queiroz, ST | 1 |
| Bag, P | 1 |
| Ojha, D | 1 |
| Mukherjee, H | 1 |
| Halder, UC | 1 |
| Mondal, S | 1 |
| Biswas, A | 1 |
| Sharon, A | 1 |
| Van Kaer, L | 1 |
| Chakrabarty, S | 1 |
| Das, G | 1 |
| Mitra, D | 1 |
| Chattopadhyay, D | 1 |
| Park, YG | 2 |
| Choi, JH | 1 |
| Lee, C | 1 |
| Kim, S | 1 |
| Kim, Y | 1 |
| Chang, KY | 1 |
| Paek, SH | 1 |
| Kim, D | 2 |
| Ananthan, S | 1 |
| Meskarian, M | 1 |
| Abbassian, H | 1 |
| Esmaeili, P | 1 |
| Tahamtan, M | 1 |
| Aghaei, I | 1 |
| Vaziri, Z | 1 |
| Sheibani, V | 1 |
| Whalley, BJ | 1 |
| Abdulrahman, AA | 1 |
| Faisal, K | 1 |
| Meshref, AA | 1 |
| Arshaduddin, M | 2 |
| Stöhr, T | 1 |
| Lekieffre, D | 1 |
| Freitag, J | 1 |
| Kolasiewicz, W | 1 |
| Kuter, K | 1 |
| Park, HY | 1 |
| Lee, CJ | 1 |
| Choi, S | 1 |
| Jo, S | 1 |
| Choi, H | 1 |
| Kim, YH | 1 |
| Shin, HS | 1 |
| Llinas, RR | 1 |
| Handforth, A | 5 |
| Homanics, GE | 2 |
| Covey, DF | 1 |
| Krishnan, K | 1 |
| Lee, JY | 1 |
| Sakimura, K | 1 |
| Martin, FC | 2 |
| Quesada, A | 3 |
| Zappalà, A | 1 |
| Parenti, R | 1 |
| La Delia, F | 1 |
| Cicirata, V | 1 |
| Cicirata, F | 1 |
| Bui, PH | 1 |
| Hankinson, O | 1 |
| Nahab, FB | 1 |
| Brown, T | 1 |
| Shin, C | 1 |
| Dong, C | 1 |
| Haubenberger, D | 1 |
| Hallett, M | 1 |
| LeDoux, MS | 1 |
| Lorden, JF | 1 |
| Monsef, HR | 1 |
| Ghobadi, A | 1 |
| Iranshahi, M | 1 |
| Abdollahi, M | 1 |
| Miwa, H | 1 |
| Hutchinson, D | 1 |
| Ho, V | 1 |
| Dodd, M | 1 |
| Dawson, HN | 1 |
| Zumwalt, AC | 1 |
| Schmitt, D | 1 |
| Colton, CA | 1 |
| Wilms, H | 1 |
| Sievers, J | 1 |
| Deuschl, G | 1 |
| Tolbert, DL | 1 |
| Clark, BR | 1 |
| Krahl, SE | 1 |
| Al-Deeb, S | 1 |
| Al-Moutaery, K | 1 |
| Biary, N | 1 |
| Tariq, M | 1 |
| Lamarre, Y | 1 |
| Joffroy, AJ | 1 |
| Dumont, M | 1 |
| De Montigny, C | 1 |
| Grou, F | 1 |
| Lund, JP | 1 |
| Battista, AF | 1 |
| Goldstein, M | 1 |
| Miyamoto, T | 1 |
| Matsumoto, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Effects of Octanoic Acid for Treatment of Essential Voice Tremor[NCT01864525] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Three experienced listeners independently rated each participant's voice from paired sample recordings comparing the baseline to post-test samples in randomized order for each condition. Sustained vowel and sentence-level recordings were rated, with decoded samples later analyzed for 1=better for post-test compared to baseline, 0= no difference between post-test and baseline. Maximum score for each participant was 3 (post-test was better for each of three raters). The range of possible scores was the sum of each of three raters' scores (0 to 3), with 0 indicating no difference between baseline and post-test voice tremor severity rating, and 3 indicating better voice (less tremor severity) at post-testing compared to pre-testing. Mean post-test values for task were compared for the octanoic acid and placebo conditions, and all raters were blind to which sample was a baseline versus a post-test recording, and which samples were associated with the [placebo or octanoic acid conditions. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2).
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Sustained vowel, summed binary ratings (0-3) | Sentence-level, summed binary ratings (0-3) | |
| Octanoic Acid | 1.53 | 1.19 |
| Placebo | 1.25 | 1.63 |
Voice recordings were used to measure the degree of tremor in the voice. Mean post-test values for each acoustic measure were compared after the octanoic acid and placebo conditions, with and without consideration of baseline values. Mean values represent the average of two testing days. Degree of amplitude tremor shows the extent of amplitude variation as a percent of the mean signal amplitude, with lower numbers indicating less amplitude tremor. Baseline values for magnitude of amplitude tremor across all participants and conditions ranged from 4.06 to 27.09, and post-test values ranged from 1.94 to 26.02. Degree of frequency tremor shows the extent of fundamental frequency variation as a percent of the mean signal frequency, with lower numbers indicating less frequency tremor. Baseline values for magnitude of frequency tremor across all participants and conditions ranged from 1.21 to 15.31, and post-test values ranged from 0.60 to 13.86. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2)
| Intervention | percentage of voice signal with tremor (Mean) | |||
|---|---|---|---|---|
| Baseline Magnitude of Acoustic Amplitude Tremor | Post-test Magnitude of Acoustic Amplitude Tremor | Baseline Magnitude of Acoustic Frequency Tremor | Post-test Magnitude of Acoustic Frequency Tremor | |
| Octanoic Acid | 13.49 | 9.35 | 5.19 | 3.98 |
| Placebo | 12.91 | 12.43 | 5.57 | 5.35 |
2 reviews available for harmaline and Disease Models, Animal
| Article | Year |
|---|---|
Rodent models of tremor.
Topics: Animals; Brain; Central Nervous System Stimulants; Disease Models, Animal; Harmaline; Humans; Mice; | 2007 |
Animal models of tremor.
Topics: Animals; Central Nervous System Diseases; Disease Models, Animal; Harmaline; Humans; Mammals; Specie | 1999 |
32 other studies available for harmaline and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Harmaline potentiates morphine-induced antinociception via affecting the ventral hippocampal GABA-A receptors in mice.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Disease Models, Animal; Drug Synergism; Drug Therapy, | 2021 |
Agmatine has beneficial effect on harmaline-induced essential tremor in rat.
Topics: Agmatine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Essential Tremor; Harm | 2021 |
Tremorolytic effect of 5'-chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats.
Topics: Adenosine A1 Receptor Agonists; Animals; Brain; Deoxyadenosines; Disease Models, Animal; Dose-Respon | 2017 |
Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Essen | 2017 |
Development of Harmaline-induced Tremor in a Swine Model.
Topics: Accelerometry; Animals; Disease Models, Animal; Harmaline; Sus scrofa; Tremor; Wireless Technology | 2018 |
In Vivo Analysis of the Climbing Fiber-Purkinje Cell Circuit in SCA2-58Q Transgenic Mouse Model.
Topics: Aging; Animals; Central Nervous System Stimulants; Cerebellum; Disease Models, Animal; Harmaline; Me | 2018 |
Anxiolytic and antidepressant effects of ACPA and harmaline co-treatment.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Arachidon | 2019 |
Accurate and affordable assessment of physiological and pathological tremor in rodents using the accelerometer of a smartphone.
Topics: Accelerometry; Animals; Central Nervous System Stimulants; Disease Models, Animal; Essential Tremor; | 2019 |
Effects of unilateral stereotactic posterior striatotomy on harmaline-induced tremor in rats.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Essential Tremo | 2013 |
A dihydro-pyrido-indole potently inhibits HSV-1 infection by interfering the viral immediate early transcriptional events.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Female; Harmaline; Herpes Simplex; Herpesvirus 1, | 2014 |
Heterogeneity of tremor mechanisms assessed by tremor-related cortical potential in mice.
Topics: Action Potentials; Animals; Cerebral Cortex; Disease Models, Animal; Harmaline; Mice; Tremor | 2015 |
Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
Topics: Amisulpride; Animals; Anti-Dyskinesia Agents; Benzothiazoles; Disease Models, Animal; Dopamine Agoni | 2016 |
Harmaline-induced amnesia: Possible role of the amygdala dopaminergic system.
Topics: Amnesia; Animals; Basolateral Nuclear Complex; Behavior, Animal; Disease Models, Animal; Dopamine Ag | 2016 |
Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor.
Topics: Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety; Avoidance Learning; Benzoxazines; Can | 2016 |
Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats.
Topics: Animals; Antioxidants; Benzaldehydes; Central Nervous System Stimulants; Disease Models, Animal; Har | 2017 |
Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats.
Topics: Acetamides; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Esse | 2008 |
Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exploratory Be | 2009 |
Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive.
Topics: Animals; Calcium Channels, T-Type; Cell Line; Disease Models, Animal; Harmaline; Humans; Male; Mice; | 2010 |
T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.
Topics: Analysis of Variance; Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; C | 2010 |
Expression of connexin57 in mouse development and in harmaline-tremor model.
Topics: Age Factors; Animals; Animals, Newborn; Central Nervous System; Central Nervous System Stimulants; C | 2010 |
Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor.
Topics: Animals; Behavior, Animal; Benzimidazoles; Cyclopropanes; Cytochrome P-450 Enzyme System; Disease Mo | 2011 |
Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor.
Topics: Animals; Caprylates; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relati | 2012 |
Abnormal spontaneous and harmaline-stimulated Purkinje cell activity in the awake genetically dystonic rat.
Topics: Action Potentials; Animals; Animals, Newborn; Disease Models, Animal; Dystonic Disorders; Harmaline; | 2002 |
Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test.
Topics: Alkaloids; Analgesics; Animals; Disease Models, Animal; Harmaline; Male; Mice; Pain; Pain Measuremen | 2004 |
Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.
Topics: 1-Octanol; Animals; Carbenoxolone; Central Nervous System Stimulants; Cerebellum; Chloroquine; Conne | 2006 |
Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.
Topics: Age Factors; Amyloid beta-Protein Precursor; Animals; Animals, Newborn; Behavior, Animal; Biomechani | 2007 |
Olivocerebellar projections modify hereditary Purkinje cell degeneration.
Topics: Animals; Behavior, Animal; Calbindins; Cell Survival; Cerebellar Cortex; Denervation; Disease Models | 2000 |
Suppression of harmaline-induced tremor in rats by vagus nerve stimulation.
Topics: Animals; Central Nervous System Stimulants; Disease Models, Animal; Electric Stimulation; Harmaline; | 2001 |
Effect of acute caffeine on severity of harmaline induced tremor in rats.
Topics: Animals; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Electromyography; Harm | 2002 |
Central mechanisms of tremor in some feline and primate models.
Topics: Animals; Brain; Cats; Cerebellum; Disease Models, Animal; Electromyography; Haplorhini; Harmaline; M | 1975 |
Effect of centrally acting drugs on experimental torticollis in monkeys.
Topics: Acetates; Alkaloids; Aminooxyacetic Acid; Animals; Brain Stem; Chlorocebus aethiops; Disease Models, | 1976 |